Cue Biopharma (NASDAQ: CUE)
Cue Biopharma Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cue Biopharma Company Info
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.
News & Analysis
3 Biotech Start-Ups That Could Soar in 2020
Concept-proving results for lead programs at these biotechs will send their stock prices soaring or sinking before the year's over.
3 Growth Stocks That Could Put Netflix's Returns to Shame
The streaming video veteran has created a lot of shareholder wealth in recent years. These stocks just might do even better in the future.
Valuation
Earnings Transcripts
Cue Biopharma, Inc. (CUE) Q1 2020 Earnings Call Transcript
CUE earnings call for the period ending March 31, 2020.
Cue Biopharma, Inc. (CUE) Q1 2020 Earnings Call Transcript
CUE earnings call for the period ending March 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.